Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug shield kidneys in lupus?

NCT ID NCT07700940

Recruiting now Disease control Sponsor: Ahmed Yehia Ismail Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This trial investigates whether empagliflozin, a drug already used to protect kidneys in diabetes, can also benefit people with lupus nephritis—a serious kidney complication of lupus. Researchers will compare empagliflozin plus standard care against a placebo plus standard care in 66 adults with active lupus nephritis. The main goal is to see if the drug improves kidney function and reduces protein in the urine over three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin 25 mg tablet
What this could lead to
If it works, this could offer a new way to protect kidney function in people with lupus nephritis, potentially slowing disease progression.
What could go wrong
This is a small, early-phase trial with only 66 participants and a short 3-month treatment period. Results may not apply to all lupus nephritis patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS (LN)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beni-Suef university hospital

    RECRUITING

    Banī Suwayf, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.